LLY

Eli Lilly's experimental Alzheimer's treatment snagged a key FDA designation on Thursday. LLY stock surged to a record high.

The Nasdaq and the S&P 500 indexes hit all-time highs on Thursday, boosted by shares of Tesla and other top-shelf technology firms as data showing fewer weekly jobless claims bolstered views of a steady recovery in the labor market. Focus was also on President Joe Biden's meeting with a bipartisan group of U.S. senators at 11:45 a.m. ET to discuss their proposed framework for a spending bill to invest in the country's bridges, roads and other physical infrastructure.

What happened Shares of Eli Lilly (NYSE: LLY) were soaring 7.8% higher at 11:05 a.m. EDT on Thursday. The big gain came after the drugmaker announced that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation to Lilly's experimental Alzheimer's disease drug donanemab.

The drug maker Eli Lilly said the FDA designated its Alzheimer's drug candidate as a breakthrough therapy. It will file for approval later this year.

Tesla, Snap and Eli Lilly punched higher, and stocks opened in rally mode Thursday as infrastructure negotiations progressed.

The Nasdaq was set to open at a record high on Thursday, boosted by shares of Tesla and other top-shelf technology firms as data showing fewer weekly jobless claims pointed to a steady recovery in the labor market. Tesla Inc rose 2.8% after Chief Executive Officer Elon Musk said he would list SpaceX's space internet venture, Starlink, when its cash flow is reasonably predictable, adding that Tesla shareholders could get preference in investing.

Stocks set for a higher open as lawmakers are signaling that an infrastructure deal could get done soon.

Stocks climbed Thursday after the number of Americans filing for first-time unemployment benefits fell last week and durable-goods orders climbed at the fastest pace this year. Marin Software surged after saying its ad management platform now lets users manage Instacart ads. Instacart is an online platform that delivers groceries and other items from nearly 55,000 stores in the U.S. and Canada.

EU approves AstraZeneca's (AZN) rare disease drug, Koselugo and expanded use of J&J's (JNJ) Darzalex Faspro and Sanofi's (SNY) Aubagio.

In honor of the 100th anniversary of the discovery of insulin, Eli Lilly and Company (NYSE: LLY) today launched the Leonard Award to recognize diverse champions dedicated to advancing diabetes management through innovative thinking and novel approaches. Nominations are being accepted now until August 31, 2021 at Lilly.com/LeonardAward.

Eli Lilly and Co said it will seek accelerated approval from the U.S. health regulator this year for its Alzheimer's candidate, weeks after a rival drug from Biogen Inc won the agency's endorsement using the same regulatory pathway. Lilly's shares jumped over 8% on Thursday, while Biogen fell nearly 5%. Biogen's Aduhelm was approved under the FDA's accelerated approval program that allows certain drugs on the market earlier based on evidence they can likely benefit patients.

By Dhirendra Tripathi

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY) investigational antibody therapy for Alzheimer's disease (AD). The Breakthrough Therapy designation aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over already available th

Eli Lilly received FDA breakthrough status for its donanemab Alzheimer's drug, speeding the agency's review of the product. The shares are higher.

Stocks moving in premarket trading Thursday include Rite Aid, Marin Software, Eli Lilly, KB Home and Roku.

By Peter Nurse

Today we will run through one way of estimating the intrinsic value of Eli Lilly and Company ( NYSE:LLY ) by taking the...

In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported citing the Washington University School of Medicine. The latest study included three of the four variants that have been designated "variants of concern" by the WHO. The FDA in April revoked the emergency use authorization of Eli Lilly And Co's (NYSE: LLY) single antibody therapy, bamlanivimab, amid resistance due to the variants.

Experimental anti-amyloid antibodies from Eli Lilly & Co (NYSE: LLY) and Roche Holding AG's (OTC: RHHBY) failed to improve symptoms of Alzheimer's disease (AD) in a Phase 2/3 study led by Washington University School of Medicine reported last year. Now, the study researchers say they have evidence that Roche's gantenerumab could help a subset of patients. In trial participants with dominantly inherited Alzheimer's disease (DIAD), which causes early onset of memory loss and other symptoms, Roche'

Style Box ETF report for FLQL